

AGENDA
CONNECTICUT MEDICAL EXAMINING BOARD
Tuesday, November 17, 2020 at 1:30 PM

Department of Public Health
410 Capitol Avenue, Hartford Connecticut

CALL TO ORDER

I. APPROVAL OF MINUTES
September 15, 2020

II. OPEN FORUM

III. UPDATES
A. Chair Updates
B. DPH Updates

IV. NEW BUSINESS
A. Review of License Reinstatement Application
Presented by Celeste Dowdell, License and Applications Analyst

- Onikepe Agebola, MD

V. OFFICE OF LEGAL COMPLIANCE
A. Roozbeh Badii, M.D.- Petition No. 2016-1045
Presentation of Motion for Summary Suspension - Presented by David Tilles, Staff Attorney, DPH
B. Fawad Hameedi, M.D. - Petition No. 2017-869
Presentation of Consent Order Modification - Presented by David Tilles, Staff Attorney, DPH

ADJOURN

This meeting will be held by video conference at the following link

Connecticut Medical Examining Board via Microsoft Teams
Join on your computer or mobile app
[Click here to join the meeting](#)

Or call in (audio only)
[+1 860-840-2075](#) - Phone Conference ID: 260 864 074#

The following minutes are draft minutes which are subject to revision and which have not yet been adopted by the Board.

**CONNECTICUT MEDICAL EXAMINING BOARD MINUTES of
September 15, 2020**

The Connecticut Medical Examining Board held a meeting on Tuesday, September 15, 2020 by video conference.

BOARD MEMBERS PRESENT: Kathryn Emmett, Esq., Chairperson
Raymond Andrews, Jr., Esq.
Allyson Duffy, MD
Marie C. Eugene, DO
Robert Green, MD
Michele Jacklin
William C. Kohlhepp, DHSc, PA-C
Edward McAnaney, Esq.
Jean Rexford
Daniel Rissi, MD
Harold Sauer, MD
David Schwindt, MD
C. Steven Wolf, MD
Andrew Yuan, DO

BOARD MEMBERS ABSENT: Brimal Patel, MD
Marilyn Katz, MD
Shawn London, MD

Ms. Emmett called the meeting to order at 1:30 p.m.

Dr. Kohlhepp was welcomed to his first meeting as a member of the Board.

I. MINUTES

The draft minutes of the July 21, 2020 meeting were reviewed. Mr. McAnaney made a motion, seconded by Dr. Sauer to approve the minutes. The motion passed with all in favor except Mr. McAnaney and Dr. Kohlhepp who abstained.

II. OPEN FORUM

None

III. UPDATES

A. Chair Updates
None

B. Department of Public Health
None

IV. NEW BUSINESS

A. Onikepe Agebola, MD – Review of License Reinstatement Application
Celeste Dowdell, License and Applications Analyst, Department of Public Health presented a license reinstatement application for Onikepe Agebola, MD.
Mr. McAnaney made a motion, seconded by Dr. Green, to table this matter for more information to be obtained. The motion passed unanimously.

Dr. Zeman joined the meeting at 1:44 p.m.

B. Sarita Mallya, MD – Review of License Reinstatement Application

Celeste Dowdell, License and Applications Analyst, Department of Public Health presented a license reinstatement application for Sarita Mallya, MD.

Dr. Green made a motion, seconded by Ms. Jacklin, to recommend reinstatement of Dr. Mallya's license.

V. OFFICE OF LEGAL COMPLIANCE

A. Lilium Ruiz (unlicensed) - Petition No. 2019-1164

Staff Attorney Linda Fazzina, Department of Public Health, presented a Cease and Desist Order in this matter. Respondent was not present.

Dr. Wolf made a motion, seconded by Dr. Green to approve the Order. The motion passed unanimously.

B. Bryan Boffi, M.D.- Petition No. 2016-1045

Staff Attorney Diane Wilan, Department of Public Health, presented a Consent Order in this matter.

Attorney Hilary Fisher Nelson was present on behalf of respondent.

Ms. Rexford. made a motion, seconded by Dr. Sauer, to approve the Consent Order which imposes a reprimand and a \$5000.00 civil penalty. The motion passed unanimously.

C. Glen Rosenfeld, M.D.- Petition No. 2019-44

Staff Attorney Linda Fazzina, Department of Public Health, presented a Consent Order in this matter.

Attorney Mary Alice Moore Leonhardt was present on behalf of respondent.

Dr. Green made a motion, seconded by Mr. McAnaney, to approve the Consent Order which imposes a \$5000.00 civil penalty. The motion passed unanimously.

VI. ADJOURNMENT

As there was no further business, the meeting was adjourned at 2:08 p.m.

Respectfully submitted,
Kathryn Emmett, Esq., Chairperson

TO: Connecticut Medical Examining Board

FROM: Celeste Dowdell
Licensing Applications Analyst
Practitioner Licensing and Investigations Section

RE: Onikepe Adegbola, MD

Dr. Adegbola is an applicant for Connecticut physician licensure reinstatement. Dr. Adegbola meets all requirements for reinstatement except she has been out of active practice.

Applicants who have been out of active clinical practice longer than six (6) months are reviewed by the Connecticut Medical Examining Board. The CMEB could require applicants who have been out of active clinical practice for longer than two years to complete the Federation of State Medical Board's Special Purpose Examination (SPEX).

Please accept this as a summary of the documentation submitted in support of Dr. Adegbola's application.

Medical Education: College of Medicine, University of Lagos, Nigeria- 1995

United States Medical Licensing Examination: Parts 1-3 completed and passed

Post Graduate Training Completed:

06/26/1997-08/15/1997: Howard University- Transitional

07/01/98-06/30/00: New York Presbyterian Hospital- Pathology Resident

07/01/05-06/30/07: Hospital of the University of Pennsylvania- Nuclear Medicine Resident

Dr. Adegbola previously held a license in Pennsylvania.
There is no history of discipline against this license.

CT license issued 6/1/2007, expired 6/30/2008

Dr. Adegbola is board certified in Nuclear Medicine

Activities since License expired:

Statements attached

Connecticut Department of Public Health
Physician Licensure
410 Capitol Ave., MS# 12APP
P.O. Box 340308
Hartford, CT 06134-0308
Fax: (860) 707-1931
8/13/2020

To Whom It May Concern:

REINSTATEMENT OF LAPSED LICENSE 045473

I am writing this statement regarding my clinical activities after I completed residency in 2007. After completion of residency, I did no clinical work, or had any clinical positions. I worked in the pharmaceutical industry until 2015 when I was laid off from Quest Diagnostics. Since 2015 I have been a stay at home mother to my triplets as well as founding and running a biotech company and a food company part time.

Sincerely,

Onikepe Adegbola, MD PhD

ONIKEPE ADEGBOLA, MD PhD

PROFESSIONAL PROFILE

- Physician-scientist with research background in oncology, and clinical background in anatomic and laboratory pathology and molecular imaging
- Expertise in biomarker strategy in drug development
- Experienced in clinical trial design and execution
- Clinical Development, Medical Affairs, and Technology Assessment expertise in Pharma and Medical Devices
- Expertise in medical strategy for product commercialization, launch and lifecycle management. Extensive experience in Medical Affairs activities from opportunity identification, product development and commercialization to launch and lifecycle management
- Strong interpersonal, influencing, presentation, and communications skills. Experience leading cross-functional teams including R&D, Safety, Commercial, Regulatory, Legal, Policy, HEOR, Patient Advocacy and Reimbursement in a highly matrixed organization.
- Consistent track record of successfully managing people and projects in various roles in the pharmaceutical and medical device industry
- Board-certified nuclear medicine physician. Connecticut Physician License, 2007-present, Pennsylvania Physician License, 2009- present
- Clinical training in anatomic pathology and clinical pathology
- Research training (PhD) in pathobiology (concentration in cancer biology)

AREAS OF EXPERTISE

molecular and cellular biology, immunobiology, biomarker discovery and strategy, imaging, translational medicine, oncology, anatomic and clinical pathology, clinical development, commercialization, Medical Affairs, pharmaceuticals, medical device

EDUCATION

The Johns Hopkins University School of Medicine, Baltimore

- PhD, Pathobiology (concentration: cancer biology), 2001-2005. Thesis: Identification and Characterization of an Interaction between pp32 and the Retinoblasoma Protein (Rb)

University Of Edinburgh, Scotland

- Clinical Oncology Elective, 1995

University of Lagos, Nigeria

- MD, 1988 - 1995

GRE General Test, April 2000, score – 2340

- Verbal - 800 (99th percentile)
- Analytical - 800 (99th percentile)
- Quantitative - 740 (85th percentile)

PROFESSIONAL EXPERIENCE

Founder. Casa de Sante, 2019- Present

CEO, A'as, Inc, 2016 – 2019

- Founder & CEO, responsible for fundraising. Obtained funding through successful grant applications for SBIR and State of Maryland grants.

Global Head, Scientific Affairs, Clinical Trials, Quest Diagnostics, May 2013 - September 2015

- Led the scientific affairs function that has both commercial and operational responsibilities
- Recruited and managed a team of 20, including 5 PhD level scientists in the scientific affairs team who are customer facing, laboratory medicine specialists that support the sales team in developing new commercial opportunities (including companion dx support)
- Supported business development and due diligence activities; developed relationships with key Pharma development personnel in order to develop a customer base for our biomarker and CDx efforts
- As interim head of Quality, ensured timely clinical trial study setup (competitive with other central labs and CROs) and eliminated errors / quality failures by 50%
- Built a network across Quest Diagnostics clinical franchises and Scientific and Innovation teams to ensure that Clinical Trials is always able to bring customers the most complete offering from Quest, including providing scientific input and strategy into clinical trial protocols; moved Quest from bottom third to top CRO in scientific expertise based on Pharma customer survey
- Ensured that the commercial and PM teams had adequate technical and scientific support, including scientific affairs plans for major customers, articles, presentations and a quarterly newsletter
- Maintained up to date knowledge of Good Laboratory Practice (GLP), Good Clinical Practice (GCP), Clinical Laboratory Improvement Act (CLIA) regulations

Chief Medical Officer, Molecular Imaging, Executive Medical Director, GE Healthcare, December 2010 – April 2013

- Lead the clinical evaluation and validation of new products (NPIs) as the leader of the clinical research team
- Lead the generation of clinical strategy and design for NPIs
- Lead and oversee GE-sponsored clinical trials, act as medical monitor for GE-sponsored trials
- Lead the design and execution of clinical studies confirming the performance of NPIs relative to specific unmet medical needs
- Build and maintain relationships with KOLs, medical societies and advocacy groups to support GE strategy and clinical adoption of products
- Act as a medical contact for the FDA and other government and regulatory agencies concerning clinical issues for MI products
- Manage clinical studies, working closely with medical facilities, academia, and CROs
- Provide subject matter expertise for patient safety and in medical risk assessments within the Post-Market Safety Review Board.
- Participate on the NPI review committee for Molecular Imaging (MI) that reviews clinical trials for merit of progression to next stage of development
- Lead publication strategy. Coordinate publication and regulatory submissions that include clinical data in support of Regulatory Affairs
- Lead and participate in medical advisory boards
- Provide direction and leadership in HEOR and CER to develop customer value propositions for new and existing products
- Support due diligence for acquisitions and intellectual property licensing

**Medical Director, US Medical Affairs, Diagnostic Imaging
Bayer HealthCare Pharmaceuticals, September 2008 – November 2010**

- Brand Medical Lead for Magnevist, the market leading MRI contrast agent. Responsible for development and execution of medical strategy to support and grow Magnevist. As medical/scientific expert led, directed or supported activities of MSL, HEOR, CME, ISS, Commercial, (Marketing, Sales, Business Development), R&D, Safety, Regulatory and Legal functions
- Member of Global Launch team for Florbetaben, an amyloid imaging agent for Alzheimer's Dementia. Responsible for US medical launch strategy and activities, working closely with R&D and Commercial teams for successful registration and launch plans including marketing and commercial strategy, market research, competitive intelligence, training programs, speaker training, advisory boards, investigator meetings, publication planning and building/maintaining relationships with neurology, psychiatry and radiology KOLs, professional organizations and patient advocacy groups
- Clinical Research Physician (Medical Expert) for Phase III/IV clinical trials

- Responsible for strategy and execution of Medical Affairs Plans, including publications, advisory boards, speaker training, CME, ISS, and Medical Information for assigned brands. Provided strategic medical input to Commercial Brand Plans
- Consultant to Commercial team on relevant acquisitions, joint ventures or other strategic partnerships for assigned brands and molecular imaging
- Developed ISS strategy and identified gaps. Evaluated investigator-initiated studies and grant requests and developed publication strategy
- Supported Public Relations and Corporate Communications to publicize relevant product information. Reviewed and edited press releases
- Identified, built and maintained relationships with KOLs and key external customers including professional organizations and advocacy groups
- Represented the Company on medical/scientific aspects of brand-specific interactions, communications and presentations with internal and external stakeholders including the FDA, KOLs, HCPs, GPOs, and customers
- Accountable for the accuracy of medical/scientific and promotional materials and other company communications for Magnevist, Eovist and Florbetaben through the medical legal regulatory review (MLR) process
- Medical Lead for cross functional team (Safety, Regulatory, R&D, Commercial, Legal, PR) on response to product safety issue (NSF)

Imaging Project Leader, Oncology Biomarkers and Imaging, Novartis Pharmaceuticals Corporation, July 2007 - August 2008

- Proactively identified relevant imaging methodologies and innovative applications to accelerate progression of oncology product candidates from preclinical to Proof of Concept (POC) and Phase I-III
- Developed the imaging biomarker strategy, including translational imaging, from preclinical to clinical development (Phase I-III) for multiple product candidates and global clinical trials (including 4 of 5 high priority oncology projects)
- Successfully integrated laboratory and imaging biomarker strategy for multiple product candidates and global clinical trials
- Integrated imaging and laboratory biomarker data and presented to clinical teams and clinical development leadership
- Evaluated and interpreted imaging biomarker data in trials and made strategic recommendations related to protocol objectives

- Oversaw and managed imaging budget for clinical trials
- Successfully led and managed global trials with a team of study managers, CROs, line functions and academic institutions. Ensured execution excellence of imaging strategy in oncology global trials in a timely manner within resources and budget
- Member of the ICT, IPT and Clinical Submission teams
- Authored the imaging biomarker portions of the Translation Medicine Plan & POC, Clinical Development Plan, Clinical Study Protocols, Investigator Brochure and Clinical Study Reports
- Authored biomarker sections/reports for INDs, Investigator Brochures, FDA briefing books, and submission documents
- Developed and authored SOPs to ensure standardization of molecular imaging techniques and data in multi-center global trials
- Identified appropriate CROs, clinical trial sites and external consultants and assisted in writing contracts and budgets

Nuclear Medicine Fellow, University of Pennsylvania School of Medicine, July 2005 - June 2007

- Comprehensive experience in all aspects of Nuclear Medicine and molecular imaging (PET/CT), including both diagnostic and therapeutic applications of radionuclides
- Prepared and delivered presentations and lectures
- Performed preclinical PET research in mice using lymphoma xenografts

PhD candidate, The Johns Hopkins University School of Medicine, Baltimore, July 2001- June 2005

- PhD, Pathobiology (concentration: cancer biology). Thesis: Identification and Characterization of an Interaction between pp32 and the Retinoblasoma Protein (Rb)

Postdoctoral Fellow, University of California San Francisco, August 2000 - July 2001

- Investigated gene expression and cell biology of yeast with microarray and molecular biology assays
- Annotated the Candida genome using computational biology

Pathology Resident, Columbia University College Of Physicians and Surgeons, July 1998 - July 2000

- Clinical training in anatomic and clinical pathology, including molecular diagnostics and molecular pathology, hematopathology, immunoserology transfusion medicine, plasmapheresis and hematology
- Trained in general laboratory management, quality assurance and control, legal issues, administration, data management, cost-benefit analysis, cost containment and human resource issues
- Assisted referring physicians with interpretation of laboratory results and decision-making to facilitate optimal patient management

AWARDS

- UNCF Merck Fellowship, 2004
- Honorable Mention, L'Oreal Women in Science Fellowship, 2004
- Johns Hopkins Dept of Pathology Young Investigator Day award, 2004
- Johns Hopkins Dept of Pathology Young Investigator Day award, 2003
- Adeoye Lambo Gold Medal for the Best Student In Psychiatry, 1992

PROFESSIONAL MEMBERSHIPS

- Society of Nuclear Medicine, Member, MI Industry Leaders Working Group
- Member, Quantitative Imaging Biomarkers Alliance
- Radiological Society of North America
- World Molecular Imaging Society, Member, Industry Board
- College of American Pathologists
- MITA, Member, MI Radiation Dose Task Force
- American MENSA Society

GENEBANK SUBMISSIONS

Dungan J, Kuo A, Newport G, Lan C-Y, Iijima,C, **Adegbola O**, Roberts J, Persson K, Donnelly S, Favoreto S, Tzung K-W, Jones T, Scherer S. and Agabian N. Annotation of the Genome of *Candida albicans*. Update to the NCBI Entrez Nucleotide Accession AACQ00000000, <http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=AACQ00000000>

PATENTS

Pasternack GR, **Adegbola O** and the Johns Hopkins University School of Medicine. Control of proliferation

and apoptosis in cancer cells. US Provisional 11/413,082

INVITED PRESENTATIONS

2nd Annual Medical Device Investigator Initiated Trials Conference, September 27-28, 2012, Chicago, IL

Strategies to Facilitate Translational Imaging in Drug Development, 2nd Imaging in Drug Development, January 23- 24, 2008, London, UK

Exploratory Imaging in Drug Development - Cost Analysis and Resource Requirements, 5th Annual Medical Imaging for Clinical Trials, February 28-29, 2008, Arlington, VA

Imaging in Drug Development, Drug Discovery & Development of Innovative Therapeutics, August 4-7, 2008, Boston, MA

Translational Imaging in Drug Development, CHI 5th *In Vivo* Molecular Imaging, November 17-19, 2008, La Jolla, CA

Enhancing Imaging Techniques and Technologies to Streamline Drug Development, Translational Imaging in Drug Development, April 2-3, 2009, London, UK

ABSTRACTS AND PUBLICATIONS

- **Adegbola, O** and Conti P, Editors, "Molecular Imaging in Clinical Trials", Springer, due 2013
- M Bathaii, JR Saffer, PH Tang, J Karp, **O Adegbola**, L Loevner and A Alavi. Comparability of quantitative SUV measurement between PET alone and PET-CT on patients scanned consecutively on PET and PET-CT scanners. (SNM 2006 meeting)
- **Adegbola O** and Pasternack GR. Phosphorylated Rb complexes with pp32 and inhibits pp32-mediated apoptosis. (oral presentation, ASIP Experimental Biology 2005 meeting)
- Lee S, Huang M, Nelson D, Pickup S, Wehrli S, **Adegbola O**, Poptani H, Delikatny E, Glickson J. *In vivo* MRS markers of response to CHOP chemotherapy in the WSU-DLCL2 human diffuse large B-cell lymphoma xenograft. *NMR Biomed.* 2008 Aug;21(7):723-33
- **Adegbola O**, Yang H, Zhuang H. Hepatobiliary scintigraphy monitoring patency of partial extent biliary diversion in a patient with progressive familial intrahepatic cholestasis. (cover) *Clin Nucl Med.* 2006 Oct;31(10):622-623
- **Adegbola O** and Pasternack GR. A pp32 - Rb complex modulates androgen receptor-dependent transcription and associates with components of the splicing machinery. *Biochem Biophys Res Commun* 2005 Aug 26;334(2):702-8
- **Adegbola O** and Pasternack GR. Phosphorylated Rb complexes with pp32 and inhibits pp32-mediated apoptosis. *J. Biol. Chem.* 2005 Apr;280(16):15497-502
- Sahin F, Kannangai R, **Adegbola O**, Wang J, Su G, Torbenson M. mTOR and P70 S6 Kinase expression in Primary Liver Neoplasms. *Clin. Can. Res.* 2004 Dec;10(24):8421-5
- Kannangai R, Sahin F, **Adegbola O**, Ashfaq R, Su GH, Torbenson M. *FHIT* mRNA and protein expression in hepatocellular carcinoma. *Mod. Pathol.* 2004 Jun;17(6):653-9

Certificate of Completion

NetCE certifies that
Onikepe Adegbola 045473
has participated in the enduring material titled
#94130 Neck Pain in Adults
on March 25, 2020
and is awarded 10
AMA PRA Category 1 Credit(s)™.

Freda S. O'Brien
Freda S. O'Brien
Director of Academic Affairs

Erin K. Meinyer
Erin K. Meinyer
Executive Director



JOINTLY ACCREDITED PROVIDER
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, NetCE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Florida CE Broker Provider #50-2405, Board of Medicine.

This activity is designed to comply with the requirements of California Assembly Bill 1195, Cultural and Linguistic Competency.



Certificate of Completion

NetCE certifies that
Onikepe Adegbola MD438058
has participated in the enduring material titled
#94130 Neck Pain in Adults
on March 25, 2020
and is awarded 10
AMA PRA Category 1 Credit(s)[™].


Freda S. O'Brien
Freda S. O'Brien
Director of Academic Affairs

Erin K. Meinyer
Erin K. Meinyer
Executive Director



JOINTLY ACCREDITED PROVIDER
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, NetCE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Florida CE Broker Provider #50-2405, Board of Medicine.

This activity is designed to comply with the requirements of California Assembly Bill 1195, Cultural and Linguistic Competency.



Certificate of Completion

NetCE certifies that
Onikepe Adegbola 045473
has participated in the enduring material titled
#90781 Colorectal Cancer
on March 25, 2020
and is awarded 15
AMA PRA Category 1 Credit(s)™.

Freda S. O'Brien *Erin K. Meinyer*
Freda S. O'Brien Erin K. Meinyer
Director of Academic Affairs Executive Director



JOINTLY ACCREDITED PROVIDER
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, NetCE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Florida CE Broker Provider #50-2405, Board of Medicine.

This activity is designed to comply with the requirements of California Assembly Bill 1195, Cultural and Linguistic Competency.



Certificate of Completion

NetCE certifies that
Onikepe Adegbola MD438058
has participated in the enduring material titled
#90781 Colorectal Cancer
on March 25, 2020
and is awarded 15
AMA PRA Category 1 Credit(s)™.

Freda S. O'Brien *Erin K. Meinyer*
Freda S. O'Brien Erin K. Meinyer
Director of Academic Affairs Executive Director



JOINTLY ACCREDITED PROVIDER
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, NetCE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Florida CE Broker Provider #50-2405, Board of Medicine.

This activity is designed to comply with the requirements of California Assembly Bill 1195, Cultural and Linguistic Competency.



Dowdell, Celeste

From: ayo dele <veneuite@yahoo.com>
Sent: Tuesday, September 15, 2020 3:29 PM
To: Dowdell, Celeste
Subject: Re: Application Status

EXTERNAL EMAIL: This email originated from outside of the organization. Do not click any links or open any attachments unless you trust the sender and know the content is safe.

Thanks for the response. Here are my replies:

1. What have you been doing since your license expired - I was working in the pharmaceutical & medical device industry (did not need a license). I was also self employed with an e-commerce business.
2. What you plan to do once license is reinstated - I will get a nonclinical job that requires an active license. I will not be seeing patients, but jobs like utilization review etc need a license.
3. If you board certification is up to date (need letter) - Board certification is not up to date
4. Reason for the 5 year gap on your CV - I had triplets, was a stay at home mom.

Onyx

O Adegbola, MD PhD

On Tuesday, September 15, 2020, 03:15:19 PM EDT, Dowdell, Celeste <celeste.dowdell@ct.gov> wrote:

The medical board reviewed your file today and still had more questions. They want to know these specific things.

1. What have you been doing since your license expired
2. What you plan to do once license is reinstated
3. If you board certification is up to date (need letter)
4. Reason for the 5 year gap on your CV

Celeste Dowdell

License and Applications Analyst

Dept. of Public Health

Practitioner Licensing & Investigations Section

Ph: 860-509-7603, #3

Fax 860-707-1931

Email: Dph.healingarts@ct.gov

SUMMARY SUSPENSION COVER SHEET

In re: Roozbeh Badii, M.D.

Petition No. 2020-417

1. Respondent is licensed in Connecticut and ten\other states. The Department does not think that he has a current or past practice in Connecticut. It is unlikely, but not known with certainty, that respondent is currently practicing medicine in any state.
2. On April 20, 2020, the Maryland State Board of Physicians (hereinafter “Maryland Board”) suspended respondent’s license following a hearing into allegations that he was “professionally, physically, or mentally incompetent” to practice. The Maryland Board also ordered respondent to enroll in the Maryland Professional Rehabilitation program. Respondent did not so enroll, but took an appeal to court. On or about October 20, 2020, the Maryland Circuit Court affirmed the Maryland Board’s decision.
3. On or about May 12, 2020, the Virginia Department of Health Professions suspended respondent’s license in that state based on the Maryland suspension.
4. In addition, respondent had entered into a Consent Order with the Maryland Board on or about September 11, 2016, by which his license was reprimanded for pre-signing prescriptions for schedule II controlled substances and permitting a nurse to sign his name on prescriptions. Various states entered reciprocal disciplinary orders.
5. For the foregoing reasons, the Department believes that respondent’s continued practice as a physician and surgeon represents a clear and immediate danger to the public health and safety. The Department respectfully requests that this Board summarily suspend respondent’s license until a full hearing on the merits can be held.

**STATE OF CONNECTICUT
DEPARTMENT OF PUBLIC HEALTH
HEALTHCARE QUALITY AND SAFETY BRANCH
CONNECTICUT MEDICAL EXAMINING BOARD**

In re: Roozbeh Badii, M.D.

Petition No. 2020-417

MOTION FOR SUMMARY SUSPENSION

The Department of Public Health (hereinafter "the Department") hereby moves in accordance with the General Statutes of Connecticut §§4-182(c) and 19a-17(c) that the Connecticut Medical Examining Board summarily suspend the license of Roozbeh Badii, M.D., to practice as a physician and surgeon in Connecticut. This motion is based on the attached Statement of Charges, Affidavits and on the Department's information and belief that the continued practice as a physician and surgeon represents a clear and immediate danger to the public health and safety.

Dated at Hartford, Connecticut this 29th day of October 2020.



Christian D. Andresen, Section Chief
Practitioner Licensing and Investigations Section
Healthcare Quality and Safety Branch

**STATE OF CONNECTICUT
DEPARTMENT OF PUBLIC HEALTH
HEALTHCARE QUALITY AND SAFETY BRANCH
CONNECTICUT MEDICAL EXAMINING BOARD**

In re: Roozbeh Badii, M.D.

Petition No. 2020-417

STATEMENT OF CHARGES

Pursuant to the General Statutes of Connecticut, §§19a-10 and 19a-14, the Department of Public Health (hereinafter "the Department") brings the following charges against Roozbeh Badii, M.D.:

COUNT ONE

1. Roozbeh Badii, M.D., of Coronado, California (hereinafter "respondent") is, and has been at all times referenced in this Statement of Charges, the holder of Connecticut physician and surgeon license number 045831.
2. At various times in 2020 and prior times, respondent has suffered an emotional disorder or mental illness that does and/or may affect his practice as a physician and surgeon.*
3. The above facts constitute grounds for disciplinary action pursuant to the General Statutes of Connecticut, §20-13c(2).

*Details are omitted for reasons of privacy.

COUNT TWO

4. Paragraph 1 is incorporated herein by reference as if set forth in full.
5. On or about April 20, 2020, the Maryland State Board of Physicians issued a Final Decision and Order in its Case No. 2219-0026, in which it found that respondent is "professionally, physically, or mentally incompetent" to practice medicine. The Final Decision and Order suspended respondent's license for at least one year and made further orders regarding remedy and reinstatement. On or about October 20, 2020, the Maryland Circuit Court for Baltimore City affirmed said Final Decision and Order.

6. The above facts constitute grounds for disciplinary action pursuant to §19a-17(f) of the Connecticut General Statutes.

THEREFORE, the Department prays that:

The Connecticut Medical Examining Board , as authorized by the General Statutes of Connecticut, §§20-13c and 19a-17, revoke or order other disciplinary action against the license of Roozbeh Badii, M.D., as it deems appropriate and consistent with law.

Dated at Hartford, Connecticut this 29th day of October 2020.



Christian D. Andresen, M.P.H., Section Chief
Practitioner Licensing and Investigations Section
Healthcare Quality and Safety Branch

soe2

**CONNECTICUT MEDICAL EXAMINING BOARD
CONSENT ORDER COVER SHEET**

Respondent: Fawad Hameedi, M.D.

Petition No. 2017-869

BIOGRAPHICAL INFORMATION:

Medical School: American University of Antigua

Year of Graduation: 2011

07/01/11-06/30/13

General
surgery

Intern/resident Long Island Jewish Hospital

Current employment:	Intermittent employment in urgent care and similar
License: 053890	Issued: March 3, 2015
Type of Practice:	See above
Board Certification:	None
Malpractice History:	None known to DPH
Past History with DPH:	None
Investigation Commenced:	July 25, 2017

THIS CONSENT ORDER DISCIPLINE:

Reprimand

Probation for two years

No solo practice

Employer reports every two months

Coursework in ethics

Comply with federal criminal sentence; probation reports if applicable

Note: Awaiting sentencing in federal court. Probation to be tolled during any period of incarceration.

DEPARTMENT SUMMARY OF THE CASE:

- DPH Licensing noted the pending criminal matter on respondent's annual renewal application
- Criminal fraud. Respondent played a relatively small part in a larger fraudulent scheme at a medical practice in New York. Respondent has pleaded guilty in federal court, and is awaiting sentencing.

WILL THIS RESULT IN A REPORT TO THE N.P.D.B. BANK?

- Yes

**STATE OF CONNECTICUT
DEPARTMENT OF PUBLIC HEALTH
HEALTHCARE QUALITY AND SAFETY BRANCH
CONNECTICUT MEDICAL EXAMINING BOARD**

In re: Fawad Hameedi, M.D.

Petition No. 2017-869

CONSENT ORDER

WHEREAS, Fawad Hameedi, M.D., of Hicksville, New York (hereinafter "respondent"), has been issued license number 053890 to practice as a physician and surgeon by the Department of Public Health (hereinafter "the Department") pursuant to Chapter 370 of the General Statutes of Connecticut, as amended; and,

WHEREAS, the Department alleges that:

1. In or about November 2015, and for approximately two years preceding, respondent was employed by a medical practice in New York, City Medical Associates, and/or affiliated business and/or professional entities (hereinafter, "CMA"). At that time, respondent had completed medical school and had completed two years of residency, but had left the residency program and was not licensed to practice as a physician in any state. On or about February 7, 2018, respondent pleaded guilty to health care fraud, in violation of 18 U.S.C. §1347 and 18 U.S.C. § 371; more particularly; he pleaded guilty to the Superseding Information in *United States of America v. Fawad Hameedi*, Docket No. 17:CR-137 (JGK), in the United States District Court for the Southern District of New York, which alleged, inter alia, that on or about November 2015, and for at least two years preceding, respondent conspired with one or more physicians and non-physicians who were employed by, or affiliated with, CMA to commit health care fraud by making false statements in requests for insurance pre-authorizations for diagnostic tests and/or in claims for insurance payment, and further alleged that, on at least one occasion, respondent falsely represented himself as another person, who was a physician, in a telephone call with a health care benefits management entity. During the court's COVID shutdown, sentencing has been postponed.

2. The above described facts constitute grounds for disciplinary action pursuant to the General Statutes of Connecticut, §20-13c, including, but not limited to §20-13c(4).

WHEREAS, respondent, in consideration of this Consent Order, has chosen not to contest this matter and agrees that for purposes of this or any future proceedings before the Connecticut Medical Examining Board (hereinafter "the Board") this Consent Order shall have the same effect as if proven and ordered after a full hearing held pursuant to §§19a-10, 19a-14 and 20-13c of the General Statutes of Connecticut.

WHEREAS, for purposes of this consent order only, the parties stipulate that the respondent's obligations of restitution and forfeiture for his participation in a larger conspiracy is approximately \$182,000.

NOW THEREFORE, pursuant to §§19a-14, 19a-17 and 20-13c of the General Statutes of Connecticut, respondent hereby stipulates and agrees to the following:

Respondent waives respondent's right to a hearing on the merits of this matter.

Respondent's license number 053890 to practice as a physician and surgeon in the State of Connecticut is hereby reprimanded.

Respondent's license shall be placed on probation for a period of two (2) years under the following terms and conditions:

- a. Respondent shall provide a copy of this Consent Order to each of his employers during the entire period of probation. Respondent shall practice medicine only in a practice setting with, and under the supervision of, a licensed physician and surgeon. Respondent shall be responsible for providing a report from said physician and surgeon not less than once every two months in the first year of probation and not less than once every three months in the second year of probation. Said report shall state whether respondent is practicing safely and effectively, in accord with standards of professional ethics, and that his billing is accurate. A report that respondent is not practicing safely and effectively and/or in accord with standards of professional ethics and/or that his billing is inaccurate shall constitute a violation of probation.

- b. Respondent shall comply with all terms of his sentence in *United States of America v. Fawad Hameedi*, Docket No. 17:CR-137 (JGK), in the United States District Court for the Southern District of New York, when it is imposed. Respondent shall provide the District Court with a copy of this Consent Order within fifteen (15) days of its effective date. Upon sentencing in said court, Respondent shall be responsible for a written report to the Department not less than once every three months from District Court Probation Office indicating that respondent is in compliance with all terms of his sentence. During any period that respondent is incarcerated pursuant to said sentence, his license no. 053890 shall be suspended and the period of probation pursuant to this paragraph shall be tolled. When any period of incarceration ends, said suspension shall end and the period of probation shall resume.
- c. Within the first six months of the probationary period, respondent shall attend and successfully complete a course in professional ethics, pre-approved by the Department. Within fifteen days of the completion of such coursework, respondent shall provide the Department with proof, to the Department's satisfaction, of the successful completion of such course(s).

All correspondence and reports are to be addressed to:

Lavita Sookram, R.N., Nurse Consultant
Practitioner Compliance and Monitoring Unit
Department of Public Health
410 Capitol Avenue, MS #12HSR
P.O. Box 340308
Hartford, CT 06134-0308

All reports required by the terms of this Consent Order shall be due according to a schedule to be established by the Department of Public Health.

Respondent shall comply with all state and federal statutes and regulations applicable to respondent's licensure.

Respondent shall pay all costs necessary to comply with this Consent Order.

Any alleged violation of any provision of this Consent Order may result in the following procedures at the discretion of the Department:

- a. The Department shall notify respondent in writing by first-class mail that the term(s) of this Consent Order have been violated, provided that no prior written consent for deviation from said term(s) has been granted.

- b. Said notification shall include the acts or omission(s) which violate the term(s) of this Consent Order.
 - c. Respondent shall be allowed fifteen (15) days from the date of the mailing of notification required in paragraph 8.a. above to demonstrate to the satisfaction of the Department that respondent has complied with the terms of this Consent Order or, in the alternative, that respondent has cured the violation in question.
 - d. If respondent does not demonstrate compliance or cure the violation within the fifteen (15) days specified in the notification of violation to the satisfaction of the Department, respondent shall be entitled to a hearing before the Board which shall make a final determination of the disciplinary action to be taken.
 - e. Evidence presented to the Board by either the Department or respondent in any such hearing shall be limited to the alleged violation(s) of the term(s) of this Consent Order.
9. During the period of probation, in the event respondent does not practice as a physician and surgeon for periods of thirty (30) consecutive days or longer, respondent shall notify the Department in writing. Such periods of times shall not be counted in reducing the probationary period covered by this Consent Order and such terms shall be held in abeyance. During such time period, respondent shall not be responsible for complying with the terms of probation of this Consent Order. In the event respondent resumes practice as a physician and surgeon, respondent shall provide the Department with thirty (30) days prior written notice. Respondent shall not return to practice as a physician and surgeon without written pre-approval from the Department. Respondent agrees that the Department, in its complete discretion, may require additional documentation from respondent and/or require respondent to satisfy other conditions or terms as a condition precedent to respondent's return to practice, including but not limited to a requirement that respondent attend and successfully complete coursework, remediation, and/or retraining pre-approved by the Department. Upon completion, respondent shall provide the Department with proof, to the Department's satisfaction, of successful completion. Respondent agrees that any return to practice as a physician and surgeon without pre-approval from the Department shall constitute a violation of this Consent Order and may subject the respondent to further disciplinary action.
10. During the period of probation, if respondent practices as a physician and surgeon outside

Connecticut, respondent shall provide written notice to the Department concerning such practice. During such time period, respondent shall not be responsible for complying with the terms of probation of this Consent Order, and such time period shall not be counted in reducing the probationary period covered by this Consent Order. Respondent may comply with the terms of probation while practicing outside Connecticut if pre-approved by the Department. In the event respondent intends to return to practice as a physician and surgeon in Connecticut, respondent shall provide the Department with thirty (30) days prior written notice and agrees to comply with all terms and conditions contained in paragraph 3 above.

11. In the event respondent violates any term of this Consent Order, said violation may also constitute grounds for the Department to seek a summary suspension of respondent's license before the Board.
12. Legal notice shall be sufficient if sent to respondent's last known address of record reported to the Practitioner Licensing and Investigations Section of the Healthcare Quality and Safety Branch of the Department, or to counsel of record for respondent.
13. This Consent Order is effective on the first day of the month immediately following the date this Consent Order is accepted and ordered by the Board.
14. This Consent Order is a public document. Respondent understands and agrees that the Department's allegations as contained in this Consent Order shall be deemed true in any subsequent proceeding before the Board in which respondent's compliance with this Consent Order or with §20-13c_ of the General Statutes of Connecticut, as amended, is at issue. Further, respondent understands that any discipline imposed by this Consent Order shall be reported to the National Practitioner Data Bank maintained by the United States Department of Health and Human Services and that all disciplinary actions will appear on respondent's physician profile pursuant to Connecticut General Statutes 20-13j.
15. In the event respondent violates a term of this Consent Order, respondent agrees immediately to refrain from practicing as a physician and surgeon, upon request by the Department, with notice to the Board, for a period not to exceed 45 days. During that time period, respondent further agrees to cooperate with the Department in its investigation of the violation, and to submit to and complete a medical, psychiatric or psychological evaluation, if requested to do so by the Department; and, that the results of the evaluation shall be submitted directly to the Department. Respondent further agrees that failure to cooperate with the Department in its investigation during said 45 day period shall

constitute grounds for the Department to seek a summary suspension of respondent's license. In any such summary action, respondent stipulates that failure to cooperate with the Department's investigation shall be considered by the Board and shall, as a matter of law, constitute a clear and immediate danger as required pursuant to Connecticut General Statutes, sections 4-182(c) and 19a-17(c). The Department and respondent understand that the Board has complete and final discretion as to whether a summary suspension is ordered.

16. Any extension of time or grace period for reporting granted by the Department shall not be a waiver or preclude the Department from taking action at a later time. The Department shall not be required to grant future extensions of time or grace periods.
17. This Consent Order and terms set forth herein are not subject to reconsideration, collateral attack or judicial review under any form or in any forum. Respondent agrees that this Consent Order shall not be subject to modification as a result of any claim that the terms contained herein may result in action by third parties, including, but not limited to, healthcare facilities and/or credentialing or licensure boards and respondent waives any right to seek reconsideration or modification of this Consent Order pursuant to §4-181a of the General Statutes of Connecticut without the express consent and agreement of the Department. Respondent assumes all responsibility for assessing such actions prior to the execution of this document. Further, this Consent Order is not subject to appeal or review under the provisions of Chapters 54 or 368a of the General Statutes of Connecticut, provided that this stipulation shall not deprive respondent of any rights that respondent may have under the laws of the State of Connecticut or of the United States.
18. This Consent Order is a revocable offer of settlement which may be modified by mutual agreement or withdrawn by the Department at any time prior to its being executed by the last signatory.
19. Respondent permits a representative of the Department to present this Consent Order and the factual basis for this Consent Order to the Board. Respondent understands that the Board has complete and final discretion as to whether this executed Consent Order is approved or accepted. Respondent hereby waives any claim of error that could be raised that is related to or arises during the course of the Board's discussions regarding whether to approve or reject this Consent Order and/or a Board member's participation during this process, through the Board member's review or comments, including but not limited to

bias or reliance on evidence outside the administrative record if this matter proceeds to a hearing on a statement of charges resulting in a proposed decision by the Board and/or a panel of the Board and a final decision by the Board.

20. Respondent has consulted with an attorney prior to signing this document.
21. The execution of this document has no bearing on any criminal liability without the written consent of the Director of the Medicaid Fraud Control Unit or the State's Attorney's Office where the allegation occurred or Bureau Chief of the applicable unit in the Chief State's Attorney's Office, or the United States Attorney for the Southern District of New York. The purpose of this Consent Order is to resolve the pending administrative license disciplinary petition only, and is not intended to affect any civil or criminal liability or defense.
22. This Consent Order embodies the entire agreement of the parties with respect to this case. All previous communications or agreements regarding the subject matter of this consent order, whether oral or written, between the parties are superseded unless expressly incorporated herein or made a part hereof.

* * * * *

I, Fawad Hameedi, M.D., have read the above Consent Order, and I stipulate and agree to the terms as set forth therein. I further declare the execution of this Consent Order to be my free act and deed.

[Signature]
Fawad Hameedi, M.D.

Subscribed and sworn to before me this 29th day of October 2020.



[Signature]
Notary Public or person authorized
by law to administer an oath or affirmation

The above Consent Order having been presented to the duly appointed agent of the Commissioner of the Department of Public Health on the 2nd day of November 2020, it is hereby accepted.

[Signature]

Christian D. Andresen, M.P.H., Section Chief
Practitioner Licensing and Investigations Section
Healthcare Quality and Safety Branch

The above Consent Order having been presented to the duly appointed agent of the _____ on the _____ day of _____ 2020, it is hereby ordered and accepted.

Kathryn Emmett, Esq., Chairperson
Connecticut Medical Examining Board